Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.

The entities involved

• Stifel →

  American investment bank

  • China and Stifel are currently top suppliers in the critical minerals market, with their market actions showing a preference for producers located outside of China.Mon 00:03
  • AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.Sun 01:33
• Deutsche Bank →

  German global banking and financial services company

  • Geopolitical risk adds to UK fiscal pressures as renewed fighting drives up oil prices, prompting economists to analyze market impacts.Mon 15:09
  • Bank of America upgraded a rating to buy and suggested a potential equity stake in a Caribbean resort chain, supported by Deutsche Bank.Mon 13:32

Related events

• Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.Sep 1
• Morgan Stanley maintained Equal Weight rating, Stifel lifted target price from $90 to $107, and TD Cowen stuck to its Hold rating for a company (implied to be Elastic).Sep 1
• Stifel lowered price target on Viking Holdings Ltd, citing European low-water risk. AQR Capital Management led by Cliff Asness tracks the company.Aug 29
• Deutsche Bank reiterated a buy rating and price objective, while Citigroup and Jefferies Financial Group issued buy ratings and price targets for an unnamed company.Jul 31
• Multiple financial institutions, including Citigroup, Royal Bank of Canada, and Deutsche Bank, issued rating changes and set target prices.Sep 12